Literature DB >> 20683489

IBD: Switching metabolism-can two drugs be better than one?

Miles P Sparrow.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20683489     DOI： 10.1038/nrgastro.2010.96

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.

Authors:  Yvette Leung; Miles P Sparrow; Marc Schwartz; Stephen B Hanauer
Journal:  J Crohns Colitis       Date:  2009-03-17       Impact factor: 9.071

Review 2.  Pharmacogenetics of thiopurines in inflammatory bowel disease.

Authors:  Luc J J Derijks; Dennis R Wong
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.

Authors:  G B Elion; A Kovensky; G H Hitchings
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

4.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.

Authors:  Miles P Sparrow; Scott A Hande; Sonia Friedman; Dingcai Cao; Stephen B Hanauer
Journal:  Clin Gastroenterol Hepatol       Date:  2007-02       Impact factor: 11.382

5.  Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.

Authors:  A Ansari; N Patel; J Sanderson; J O'Donohue; J A Duley; T H J Florin
Journal:  Aliment Pharmacol Ther       Date:  2009-12-15       Impact factor: 8.171

6.  Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.

Authors:  A Ansari; T Elliott; B Baburajan; P Mayhead; J O'Donohue; P Chocair; J Sanderson; J Duley
Journal:  Aliment Pharmacol Ther       Date:  2008-09-15       Impact factor: 8.171

7.  Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.

Authors:  Richard B Gearry; Murray L Barclay; Michael J Burt; Judith A Collett; Bruce A Chapman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-08       Impact factor: 2.890

8.  6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.

Authors:  Marla C Dubinsky; Eric A Vasiliauskas; Hardeep Singh; Maria T Abreu; Kostas A Papadakis; Tram Tran; Paul Martin; John M Vierling; Stephen A Geller; Stephan R Targan; Fred F Poordad
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

9.  Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease.

Authors:  M A Smith; A M Marinaki; M Arenas; M Shobowale-Bakre; C M Lewis; A Ansari; J Duley; J D Sanderson
Journal:  Aliment Pharmacol Ther       Date:  2009-06-03       Impact factor: 8.171

10.  Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).

Authors:  Anthony M Marinaki; Azhar Ansari; John A Duley; Monica Arenas; Satoshi Sumi; Cathryn M Lewis; El-Monsor Shobowale-Bakre; Emilia Escuredo; Lynette D Fairbanks; Jeremy D Sanderson
Journal:  Pharmacogenetics       Date:  2004-03
  10 in total
  1 in total

Review 1.  Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Mehmet Coskun; Casper Steenholdt; Nanne K de Boer; Ole Haagen Nielsen
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 5.577
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.